




Instance: composition-en-d047904bec391590dca84caa3af7d489
InstanceOf: CompositionUvEpi
Title: "Composition for datscan Package Leaflet"
Description:  "Composition for datscan Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp3aba7834c46e7f3118f16adafaa76c24)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - datscan"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What DaTSCAN is and what it is used for </li>
<li>What you need to know before DaTSCAN is used </li>
<li>How DaTSCAN is used </li>
<li>Possible side effects </li>
<li>How DaTSCAN is stored </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What datscan is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What datscan is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>DaTSCAN contains the active substance ioflupane (123I) which is used to help identify (diagnose) 
conditions in the brain. It belongs to a group of medicines called  radiopharmaceuticals , which contain 
a small amount of radioactivity.<br />
<em> When a radiopharmaceutical is injected, it collects in a specific organ or area of the body for a 
short time.<br />
</em> Because it contains a small amount of radioactivity it can be detected from outside the body using 
special cameras.<br />
* A picture, known as a scan, can be taken. This scan will show exactly where the radioactivity is 
inside the organ and the body. This can give the doctor valuable information about how that organ 
is working. </p>
<p>When DaTSCAN is injected into an adult, it is carried around the body in the blood. It collects in a small 
area of your brain. Changes in this area of the brain occur in: 
* Parkinsonism (including Parkinson s disease) and<br />
* dementia with Lewy bodies.  </p>
<p>A scan will give your doctor information about any changes in this area of your brain. Your doctor may 
feel that the scan would help in finding out more about your condition and deciding on possible 
treatment. </p>
<p>When DaTSCAN is used, you are exposed to small amounts of radioactivity. This exposure is less than 
in some types of X-ray investigation. Your doctor and the nuclear medicine doctor have considered that 
the clinical benefit of this procedure with the radiopharmaceutical outweighs the risk of being exposed 
to these small amounts of radiation. </p>
<p>This medicine is used for diagnostic use only. It is used only to identify illness. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take datscan"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take datscan"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>DaTSCAN must not be used<br />
* if you are allergic to ioflupane or any of the other ingredients of this medicine (listed in section 6). 
* if you are pregnant  </p>
<p>Warnings and precautions 
Talk to your nuclear medicine doctor before using DaTSCAN if you have a moderate or severe problem 
with your kidneys or liver.  </p>
<p>Children and adolescents </p>
<p>DaTSCAN is not recommended for children aged 0 to 18 years  </p>
<p>Other medicines and DaTSCAN 
Tell your nuclear medicine doctor if you are taking or have recently taken any other medicines.<br />
Some medicines or substances can affect the way that DaTSCAN works.<br />
These include: 
* buproprion (used to treat depression (sadness)) 
* benzatropine (used to treat Parkinson s disease) 
* mazindol (reduces appetite, as a means to treat obesity)<br />
<em> sertraline (used to treat depression (sadness)) 
* methylphenidate (used to treat hyperactivity in children and narcolepsy (excessive sleepiness)) 
* phentermine (reduces appetite, as a means to treat obesity)<br />
</em> amfetamine (used to treat hyperactivity in children and narcolepsy (excessive sleepiness); also a 
drug of abuse) 
* cocaine (sometimes used as an anaesthetic for nose surgery; also a drug of abuse) </p>
<p>Some medicines may reduce the quality of the picture obtained. The doctor may ask you to stop taking 
them for a short time before you receive DaTSCAN.  </p>
<p>Pregnancy and breast-feeding 
Do not use DaTSCAN if you are pregnant or think you may possibly be pregnant. This is because the 
child may receive some of the radioactivity. Tell your nuclear medicine doctor if you think you might be 
pregnant.  Alternative techniques which do not involve radioactivity should be considered. </p>
<p>If you are breast-feeding, your nuclear medicine doctor may delay the use of DaTSCAN, or ask you to 
stop breast-feeding. It is not known whether ioflupane (123I) is passed into breast milk.<br />
<em> You should not breast-feed your child for 3 days after DaTSCAN is given.<br />
</em> Instead use formula feed for your child. Express your breast milk regularly and throw away any 
breast milk you have expressed.<br />
* You will need to continue to do this for 3 days, until the radioactivity is no longer in your body.   </p>
<p>Driving and using machines 
DaTSCAN has no known influence on the ability to drive and use machines. </p>
<p>DaTSCAN contains alcohol (ethanol) 5 % by volume. Each dose contains up to 197 mg alcohol. This is 
about the same as 5 ml beer, or 2 ml wine. This is harmful for those suffering from alcoholism and needs 
to be taken into account in pregnant or breastfeeding women, children and high risk groups such as 
patients with liver disease or epilepsy. Tell your doctor if any of these apply to you.  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take datscan"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take datscan"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>There are strict laws on the use, handling and disposal of radioactivity. DaTSCAN will always be used 
in a hospital or a similar place. It will only be handled and given to you by people who are trained and 
qualified to use it safely. They should tell you anything you need to do for the safe use of this medicine. </p>
<p>Your nuclear medicine doctor will decide the dose that is best for you.  </p>
<p>Before you receive DaTSCAN, your nuclear medicine doctor will ask you to take some tablets or liquid 
that contain iodine. These stop the radioactivity building-up in your thyroid gland. It is important that 
you take the tablets or liquid as the doctor tells you. </p>
<p>DaTSCAN is given to you as an injection, usually into a vein in your arm. The recommended 
radioactivity given by injection is between 111 to 185 MBq (megabequerel or MBq is a unit used to 
measure radioactivity). A single injection is enough. The camera pictures are usually taken 3 to 6 hours 
after the injection of DaTSCAN. </p>
<p>If you are given more DaTSCAN than you should 
Since DaTSCAN is given by a doctor under controlled conditions, it is unlikely that you will get an 
overdose. Your nuclear medicine doctor will suggest that you drink plenty of fluids to help the body get 
rid of the medicine. You will need to be careful with the water (urine) that you pass - your doctor will tell 
you what to do. This is normal practice with medicines like DaTSCAN. Any ioflupane (123I) which 
remains in your body will naturally lose its radioactivity. </p>
<p>If you have any further questions on the use of this medicine, ask your nuclear medicine doctor who 
supervises the procedure.  </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, DaTSCAN can cause side effects, although not everybody gets them.<br />
The frequency of side effects is: </p>
<p>Common:  may affect up to 1 in 10 people 
-  Headache </p>
<p>Uncommon:  may affect up to 1 in 100 people 
-  Increased appetite 
-  Dizziness 
-  Taste disturbance 
-  Nausea 
-  Dry mouth 
-  Vertigo 
-  A brief irritating feeling similar to ants crawling over your skin (formication) 
-  Intense pain (or burning sensation) at the injection site. This has been reported among <br />
    patients receiving DaTSCAN into a small vein.  </p>
<p>Not known: frequency cannot be estimated from the available data. </p>
<ul>
<li>Hypersensitivity (allergic) </li>
<li>Shortness of breath   </li>
<li>Redness of the skin   </li>
<li>Itching   </li>
<li>Rash </li>
<li>Hives (urticaria) </li>
<li>Excessive sweating   </li>
<li>Vomiting </li>
<li>Low blood pressure   </li>
<li>Feeling hot </li>
</ul>
<p>The amount of radioactivity in the body from DaTSCAN is very small. It will be passed out of the body 
in a few days without need for you to take special precautions.  </p>
<p>Reporting of side effects 
If you get any side effects, talk to your nuclear medicine doctor. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system listed 
in Appendix V.  By reporting side effects you can help provide more information on the safety of this 
medicine.  </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store datscan"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store datscan"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>You will not have to store this medicine. This medicine is stored under the responsibility of the specialist 
in appropriate premises. Storage of radiopharmaceuticals will be in accordance with national regulation 
on radioactive materials.  </p>
<p>The following information is intended for the specialist only: 
* Keep this medicine out of the sight and reach of children. 
* Do not store above 25 C.<br />
* Do not freeze. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and vial after EXP. The 
expiry date refers to the last day of that month.  Hospital staff will ensure that the product is stored and 
thrown away correctly and not used after the expiry date stated on the label.  </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What DaTSCAN contains 
* The active substance is ioflupane (123I). Each ml of solution contains ioflupane (123I) 74 MBq at<br />
reference time (0.07 to 0.13  g/ml of ioflupane).<br />
* The other ingredients are acetic acid, sodium acetate, ethanol and water for injections. </p>
<p>What DaTSCAN looks like and contents of the pack 
DaTSCAN is a 2.5 or 5 ml colourless solution for injection, supplied in a single colourless 10 ml glass 
vial sealed with a rubber closure and metal overseal. <br />
Marketing Authorisation Holder and Manufacturer 
GE Healthcare B.V. 
De Rondom 8 
5612 AP, Eindhoven<br />
The Netherlands </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien<br />
GE Healthcare<br />
T l/Tel: +32 (0) 2 719 7Lietuva 
VitaFARMA UAB 
Tel.: +370 37 225<br />
GE Healthcare Bulgaria EOOD 
Te : +359 2 9712Luxembourg/Luxemburg<br />
GE Healthcare<br />
Belgi /Belgique/Belgien 
T l/Tel: +32 (0) 2 719 7 esk  republika 
M.G.P. spol. s r.o. 
Tel.: +420 577 212 Magyarorsz g 
Radizone Diagnost-X Kft. 
Tel: +36 1 787-5Danmark 
GE Healthcare A/S 
Tlf: +45 70 2222 Malta 
Pharma-Cos Ltd. 
Tel: + 356 22266Deutschland 
GE Healthcare Buchler GmbH &amp; Co. KG 
Tel: +49 (0) 5 307 93 Nederland 
GE Healthcare B.V. 
Tel: +31 (0) 40 299 10 Eesti 
GE Healthcare Estonia O<br />
Tel: +372 6260 Norge 
GE Healthcare AS 
Tlf: +47 23 18 50 <br />
GE Healthcare A.E. 
 : +30 210 8930 sterreich 
GE Healthcare Handels GmbH 
Tel: +43 (0) 1 97272-0 </p>
<p>Espa a 
GE Healthcare Bio-Sciences, S.A.U 
Tel: +34 91 663 25 Polska 
GE Medical Systems Polska Sp. z o.o. 
Tel: +4822 330 83 France 
GE Healthcare SAS 
T l: +33 1 34 49 54 Portugal 
Satis   GE Healthcare 
Tel: +351 214251Hrvatska 
BIOVIT d.o.o. 
Tel: + 385 42 260 Rom nia 
MagnaPharm Marketing &amp; Sales Romania 
S.R.L. 
Tel: + 40 372 502 Ireland 
GE Healthcare Limited UK 
Tel: +44 (0) 1494 54 5Slovenija 
Biomedis M.B. trgovina d.o.o. 
Tel: +386 2 4716 sland 
Icepharma 
S mi: + 354 540 8Slovensk  republika 
MGP, spol. s r. o. 
Tel: +421 2 5465 4Italia 
GE Healthcare S.r.l. 
Tel: +39 02 26001 Suomi/Finland 
Oy GE Healthcare Bio-Sciences Ab 
Puh/Tel: +358 10 39<br />
Phadisco Ltd 
 : +357 22 715Sverige 
GE Healthcare AB 
Tel: +46 (0) 8 559 504 Latvija 
General Electric International Inc. 
Tel: +371 6780 7United Kingdom (Northern Ireland) 
GE Healthcare Limited 
Tel: +44(0)1494 54 5This leaflet was last revised in &lt;{MM/YYYY} </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site; 
http://www.ema.europa.eu. </p>
<p>This leaflet is available in all EU/EEA languages on the European Medicines Agency website. </p>         </div>"""      



Instance: composition-da-d047904bec391590dca84caa3af7d489
InstanceOf: CompositionUvEpi
Title: "Composition for datscan Package Leaflet"
Description:  "Composition for datscan Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp3aba7834c46e7f3118f16adafaa76c24)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - datscan"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse  </li>
<li>Det skal De vide, før De bliver undersøgt med DaTSCAN </li>
<li>Sådan skal DaTSCAN bruges </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger  </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What datscan is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What datscan is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>DaTSCAN indeholder det aktive stof ioflupan (123I), der anvendes som hjælp til at identificere 
(diagnosticere) sygdomme i hjernen. Det tilhører en gruppe lægemidler, der kaldes ”radioaktive 
lægemidler”, som indeholder en lille mængde radioaktivitet. </p>
<ul>
<li>
<p>Når et radioaktivt lægemiddel, injiceres, samler det sig sammen i et specifikt organ eller 
bestemte dele af kroppen i kort tid.  </p>
</li>
<li>
<p>Da det indeholder en lille mængde radioaktivitet, kan det påvises udefra ved anvendelse af 
specielle kameraer. </p>
</li>
<li>
<p>Der kan tages et billede, der kaldes en scanning. Dette scanningsbillede vil vise præcist, hvor 
radioaktiviteten befinder sig inden i organet eller i kroppen. Dette kan give lægen værdifuld 
information om, hvorledes organet fungerer. </p>
</li>
</ul>
<p>Når en voksen får injiceret DaTSCAN, bliver det ført rundt i kroppen med blodet. Det samler sig i et 
lille område af Deres hjerne. Forandringer i denne del af hjernen forekommer ved: </p>
<ul>
<li>
<p>Parkinsonisme (herinder Parkinsons sygdom) og  </p>
</li>
<li>
<p>demens med Lewy-legemer  </p>
</li>
</ul>
<p>En scanning vil give Deres læge information om enhver ændring i dette område af Deres hjerne. 
Deres læge kan synes, at den viden, scanningen har givet, kan hjælpe med til at finde ud af mere om 
Deres tilstand og ved beslutningen om mulig behandling. </p>
<p>Når De får DaTSCAN, eksponeres De for en lille mængde radioaktivitet. Denne eksponering er 
mindre end under visse former for røntgenundersøgelser. Deres læge og den nuklearmedicinske læge 
har vurderet at de kliniske fordele ved denne undersøgelse med det "radioaktive lægemiddel", 
overstiger risikoen for at blive udsat for disse små mængder stråling. </p>
<p>Denne medicin bruges udelukkende til diagnostiske formål. Den bruges kun til at identificere sygdom. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take datscan"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take datscan"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>DaTSCAN må ikke bruges  </p>
<ul>
<li>
<p>hvis De er allergisk over for ioflupan eller et af de øvrige indholdsstoffer i DaTSCAN 
(angivet i afsnit 6). </p>
</li>
<li>
<p>hvis De er gravid. </p>
</li>
</ul>
<p>Advarsler og forsigtighedsregler 
Tal med den nuklearmedicinske læge før DaTSCAN bliver givet til Dem hvis De har moderate eller 
svære problemer med nyrer eller lever. </p>
<p>Børn og unge 
DaTSCAN anbefales ikke til børn i alderen 0 til 18 år  </p>
<p>Brug af anden medicin sammen med DaTSCAN 
Fortæl det altid til den nuklearmedicinske læge, hvis De bruger anden medicin eller har gjort det for 
nylig. Nogle lægemidler og præparater kan påvirke den måde, DaTSCAN virker på.<br />
De omfatter: </p>
<ul>
<li>
<p>buproprion (anvendes til at behandle depression (nedtrykthed)) </p>
</li>
<li>
<p>benzatropin (anvendes til at behandle Parkinsons sygdom) </p>
</li>
<li>
<p>mazindol (nedsætter appetitten, et middel til at behandle fedme) </p>
</li>
<li>
<p>sertralin (anvendes til at behandle depression (nedtrykthed)) </p>
</li>
<li>
<p>methylphenidat (anvendes til at behandle hyperaktivitet hos børn og narkolepsi (overdreven 
søvnighed)) </p>
</li>
<li>
<p>phentermin (nedsætter appetitten, et middel til at behandle fedme) </p>
</li>
<li>
<p>amphetamin (anvendes til at behandle hyperaktivitet hos børn og narkolepsi (overdreven 
søvnighed), også et stof til misbrug) </p>
</li>
<li>
<p>cocain (anvendes til tider som et anæstetikum ved næsekirurgi; også et misbrugsstof) </p>
</li>
</ul>
<p>Visse lægemidler kan reducere den opnåede billedkvalitet. Lægen vil eventuelt bede Dem om at holde 
op med at tage dem i en kort periode, inden De får DaTSCAN. </p>
<p>Graviditet og amning 
De må ikke få DaTSCAN, hvis De er gravid eller tror, at De muligvis kan være gravid. Dette er, 
fordi barnet muligvis kan få tilført noget af radioaktiviteten. Informer den nuklearmedicinske læge, 
hvis De tror, De kunne være gravid. Andre teknikker, som ikke involverer radioaktivitet, skal 
overvejes. </p>
<p>Hvis De ammer, kan den nuklearmedicinske læge eventuelt udsætte anvendelsen af DaTSCAN eller 
bede Dem om at ophøre med at amme. Det vides ikke, om ioflupan (123I) går over i brystmælken. </p>
<ul>
<li>
<p>De bør ikke amme Deres barn de første 3 dage efter, at der er givet DaTSCAN. </p>
</li>
<li>
<p>Brug i stedet modermælkserstatning til barnet. Malk regelmæssigt brystmælken ud og kasser al 
den udmalkede mælk. </p>
</li>
<li>
<p>De skal fortsætte med at gøre dette i 3 dage, indtil der ikke længere er radioaktivitet tilbage i 
kroppen. </p>
</li>
</ul>
<p>Trafik- og arbejdssikkerhed 
DaTSCAN har ingen kendt indflydelse på evnen til at føre motorkøretøj og betjene maskiner. </p>
<p>DaTSCAN indeholder alkohol (ethanol), 5 volumen%. Hver dosis indeholder op til 197 mg alkohol. 
Dette er ca. det samme som 5 ml øl eller 2 ml vin. Dette er skadeligt for dem, der lider af alkoholisme, 
og det skal tages med i overvejelserne ved anvendelse hos gravide eller ammende kvinder, børn og 
højrisikogrupperne, såsom patienter med leversygdom eller epilepsi. Fortæl det til lægen, hvis noget af 
dette gælder for Dem.  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take datscan"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take datscan"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Der er streng lovgivning om anvendelse, håndtering og bortskaffelse af radioaktivitet. DaTSCAN vil 
altid blive anvendt på et hospital eller et lignende sted. Det vil kun blive håndteret og givet til Dem af 
personer med træning og kvalifikationer i at anvende det sikkert. De vil fortælle Dem alt, hvad De skal 
gøre for sikker brug af denne medicin.  Deres nuklearmedicinske læge vil fastsætte den dosis, der passer 
bedst til Dem.  </p>
<p>Før De får DaTSCAN, vil Deres nuklearmedicinske læge bede Dem om at tage tabletter eller væske, der 
indeholder jod. Det vil standse ophobningen af radioaktivitet i Deres skjoldbruskkirtel. Det er vigtigt, at 
De tager tabletterne eller væsken, som lægen giver Dem besked om. </p>
<p>De vil få DaTSCAN som en injektion, sædvanligvis i en blodåre i armen. Den anbefalede 
radioaktivitet ved en enkelt injektion er mellem 111 og 185 MBq (megabequerel eller MBq er en 
enhed, som anvendes til at måle radioaktivitet). En enkelt injektion er nok. Kamerabillederne bliver 
normalt taget 3 til 6 timer efter injektionen af DaTSCAN. </p>
<p>Hvis De har fået for meget DaTSCAN 
Eftersom DaTSCAN gives af en læge under kontrollerede forhold, er det usandsynligt, at De vil få en 
overdosis. Deres nuklearmedicinske læge vil foreslå, at De drikker meget væske for at hjælpe 
kroppen med at slippe af med medicinen. De skal være omhyggelig med det vand (urin), De lader – 
Deres læge vil fortælle Dem, hvad De skal gøre. Dette er normal praksis for lægemidler som 
DaTSCAN. Det ioflupan (123I), som forbliver i Deres krop, vil naturligt miste dets radioaktivitet. </p>
<p>Hvis De har flere spørgsmål til brugen af dette lægemiddel, kan De spørge Deres nuklearmedicinske 
læge. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>DaTSCAN kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger.<br />
Hyppigheden af bivirkninger er: </p>
<p>Almindelig: kan forekomme hos op til 1 ud af 10 behandlede 
-  Hovedpine </p>
<p>Ikke almindelig: kan forekomme hos op til 1 ud af 100 behandlede 
-  Øget appetit 
-  Svimmelhed 
-  Smagsforstyrrelser 
-  Kvalme 
-  Mundtørhed 
-  Svimmelhed 
-  En let irriterende følelse af, at der er myrer, der kravler på Deres hud (myrekryb) 
-  Intens smerte (eller brændende fornemmelse) ved injektionsstedet. Dette er blevet rapporteret <br />
    hos patienter, der får DaTSCAN i en lille blodåre.  </p>
<p>Ikke kendt: hyppigheden kan ikke estimeres ud fra forhåndenværende data. 
- Overfølsomhed (allergi) 
- Åndenød 
- Rødme af huden 
- Kløe 
- Udslæt 
- Nældefeber (urtikarielt) 
- Overdreven svedtendens 
- Opkastning 
- Lavt blodtryk </p>
<ul>
<li>Varmefølelse </li>
</ul>
<p>Mængden af radioaktivitet i kroppen fra DaTSCAN er meget lille. Den vil blive udskilt af kroppen i 
løbet af nogle få dage, uden at De behøver at tage særlige forholdsregler. </p>
<p>Indberetning af bivirkninger 
Hvis De oplever bivirkninger, bør De tale med Deres nuklearmedicinske læge. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. De eller Deres pårørende kan også 
indberette bivirkninger direkte til Sundhedsstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan De hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel.  </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store datscan"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store datscan"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>De skal ikke opbevare dette lægemiddel. Dette lægemiddel opbevares på en dertil bestemt lokalitet 
under ansvar af specialisten. Opbevaring af radioaktive lægemidler foregår i henhold til nationale 
bestemmelser vedrørende radioaktive materialer. </p>
<p>Følgende information er udelukkende beregnet for specialisten: </p>
<ul>
<li>
<p>Lægemidlet skal opbevares utilgængeligt for børn. </p>
</li>
<li>
<p>Må ikke opbevares ved temperaturer over 25 °C.  </p>
</li>
<li>
<p>Må ikke nedfryses.  </p>
</li>
</ul>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på kartonen og hætteglasset efter Exp. 
Udløbsdatoen er den sidste dag i den nævnte måned. Hospitalets personale sørger for, at produktet 
opbevares og bortskaffes korrekt og ikke anvendes efter udløbsdatoen angivet på etiketten. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvad DaTSCAN indeholder </p>
<ul>
<li>
<p>Det aktive stof er ioflupan (123I). Hver ml opløsning indeholder ioflupan (123I) 74 MBq på 
referencetidspunktet for aktivitet (0,07 til 0,13 μg/ml ioflupan). </p>
</li>
<li>
<p>De øvrige indholdsstoffer er eddikesyre, natriumacetat, ethanol og vand til injektionsvæsker. </p>
</li>
</ul>
<p>DaTSCANS udseende og pakningstørrelse 
DaTSCAN er en 2,5 eller 5 ml injektionsvæske, opløsning, leveret i ét enkelt farveløst 10 ml hætteglas 
forseglet med en gummilukke og metalforsegling. </p>
<p>Indehaveren af markedsføringstilladelsen og fremstiller </p>
<p>GE Healthcare B.V. 
De Rondom 8 
5612 AP, Eindhoven<br />
Holland </p>
<p>Hvis De vil have yderligere oplysninger om DaTSCAN, skal De henvende Dem til den lokale 
repræsentant. </p>
<p>België/Belgique/Belgien<br />
GE Healthcare<br />
Tél/Tel: +32 (0) 2 719 7 
Lietuva 
VitaFARMA UAB 
Tel.: +370 37 225 
България 
GE Healthcare Bulgaria EOOD 
Teл: + 359 2 9712Luxembourg/Luxemburg<br />
GE Healthcare<br />
België/Belgique/Belgien 
Tél/Tel: +32 (0) 2 719 7 
Česká republika 
M.G.P. spol. s r.o. 
Tel.: +420 577 212 Magyarország 
Radizone Diagnost-X Kft. 
Tel: +36 1 787-5 
Danmark 
GE Healthcare A/S 
Tlf: +45 70 2222 Malta 
Pharma-Cos Ltd. 
Tel:  +356 22266 
Deutschland 
GE Healthcare Buchler GmbH &amp; Co. KG 
Tel: +49 (0) 5 307 93 Nederland 
GE Healthcare B.V. 
Tel: +31 (0) 40 299 10 00  </p>
<p>Eesti 
GE Healthcare Estonia OÜ 
Tel: +372 6260 Norge 
GE Healthcare AS 
Tlf: + 47 23 18 50<br />
Ελλάδα 
GE Healthcare A.E. 
Τηλ: +30 210 8930Österreich 
GE Healthcare Handels GmbH 
Tel: +43 (0) 1 97272-0 </p>
<p>España 
GE Healthcare Bio-Sciences, S.A.U 
Tel: +34 91 663 25 Polska 
GE Medical Systems Polska Sp. z o.o. 
Tel: + 4822 330 83<br />
France 
GE Healthcare SAS 
Tél: +33 1 34 49 54 Portugal 
Satis – GE Healthcare 
Tel: + 351 214251 
Hrvatska 
BIOVIT d.o.o. 
Tel: + 385 42 260 România 
MagnaPharm Marketing &amp; Sales Romania 
S.R.L. 
Tel: + 40 372 502<br />
Ireland 
GE Healthcare Limited UK 
Tel: +44 (0) 1494 54 5 
Slovenija 
Biomedis M.B. trgovina d.o.o. 
Tel: + 386 2 4716Ísland 
Icepharma 
Sími: + 354 540 8Slovenská republika 
MGP, spol. s r. o. 
Tel: +421 2 5465 4 
Italia 
GE Healthcare S.r.l. 
Tel: +39 02 26001 Suomi/Finland 
Oy GE Healthcare Bio-Sciences Ab 
Puh/Tel: +358 10 39 
Κύπρος 
Phadisco Ltd 
Τηλ: +357 22 715Sverige 
GE Healthcare AB 
Tel: + 46 (0) 8 559 504  </p>
<p>Latvija 
General Electric International Inc. 
Tel: +371 6780 7United Kingdom (Northern Ireland) 
GE Healthcare Limited 
Tel: +44 (0) 1494 54 5 </p>
<p>Denne indlægsseddel blev senest ændret &lt;{MM/ÅÅÅÅ}   </p>
<p>De kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>
<p>Denne indlægsseddel findes på alle EU-/EØS-sprog på Det Europæiske Lægemiddelagenturs 
hjemmeside.   </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-d047904bec391590dca84caa3af7d489
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for datscan Package Leaflet for language en"
Description: "ePI document Bundle for datscan Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-d047904bec391590dca84caa3af7d489"
* entry[0].resource = composition-en-d047904bec391590dca84caa3af7d489

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpd047904bec391590dca84caa3af7d489"
* entry[=].resource = mpd047904bec391590dca84caa3af7d489
                            
                    
Instance: bundlepackageleaflet-da-d047904bec391590dca84caa3af7d489
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for datscan Package Leaflet for language da"
Description: "ePI document Bundle for datscan Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-d047904bec391590dca84caa3af7d489"
* entry[0].resource = composition-da-d047904bec391590dca84caa3af7d489

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpd047904bec391590dca84caa3af7d489"
* entry[=].resource = mpd047904bec391590dca84caa3af7d489
                            
                    



Instance: mpd047904bec391590dca84caa3af7d489
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product datscan"
Description: "datscan"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/00/135/001 (2.5 ml)"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "This medicinal product is for diagnostic use only."


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "datscan"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: d047904bec391590dca84caa3af7d489ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "datscan"

* status = #current
* mode = #working

* title = "List of all ePIs associated with datscan"

* subject = Reference(mp3aba7834c46e7f3118f16adafaa76c24)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#datscan "datscan"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-d047904bec391590dca84caa3af7d489) // datscan en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-d047904bec391590dca84caa3af7d489) // datscan da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-d047904bec391590dca84caa3af7d489
InstanceOf: List

* insert d047904bec391590dca84caa3af7d489ListRuleset
    